Sort
21,281 grants matching “influenza”
Structural Biology of Influenza Epitopes
$1,000,656Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Structural Biology of Influenza Epitopes
$1,000,090Audray Harris · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform
$1,000,088Lyndsey Linke · Sivec Biotechnologies, Llc · R44 · FY2022 · AI
Development of novel immunotherapy for influenza virus infection
$1,000,001Kazue Takahashi · Massachusetts General Hospital · U01 · FY2007 · AI
A single antiviral to treat multiple opportunistic infections
$1,000,000Stacy Remiszewski · Evrys Bio, Llc · R44 · FY2021 · AI
Vaccine and Treatment Evaluation Units
$1,000,000David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2011 · AI
Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f
$1,000,000Hong Cai · Mesa Tech International, Inc. · R44 · FY2014 · AI
Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe
$1,000,000Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2011 · AI
Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine
$1,000,000Paul Joseph Utz · Stanford University · R01 · FY2016 · AI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.
$1,000,000Christopher H Clegg · Tria Bioscience Corporation · R44 · FY2013 · AI
Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f
$1,000,000Hong Cai · Mesa Tech International, Inc. · R44 · FY2015 · AI
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2020 · AI
Identification and validation of influenza host factors as therapeutic targets
$1,000,000David E Root · Massachusetts Institute Of Technology · U01 · FY2007 · AI
Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f
$1,000,000Hong Cai · Mesa Tech International, Inc. · R44 · FY2016 · AI
The Incidence and Etiology of Influenza-Associated Pneumonia in Hospitalized Pers
$1,000,000Kathryn Margaret Edwards · Vanderbilt University · U18 · FY2009 · IP
Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections
$1,000,000Vamsee K Pamula · Baebies, Inc. · R44 · FY2021 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,000,000Jeffrey S Glenn · Stanford University · R01 · FY2017 · AI
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia
$1,000,000Jodi K Craigo · Cytoagents, Inc. · R44 · FY2022 · AI
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$1,000,000Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2022 · AI
Therapeutic factor XI blockade for sepsis
$1,000,000Erik Ian Tucker · Aronora, Inc. · R44 · FY2012 · AI
New Vaccine Surveillance Network
$1,000,000John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · IP
A single antiviral to treat multiple opportunistic infections
$1,000,000Stacy Remiszewski · Evrys Bio, Llc · R44 · FY2020 · AI
Enhanced Surveillance for Newly preventable Diseases (ARI and AGE Surveillance) Rochester, NY
$1,000,000Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2017 · IP
STRENGHTENING & INTEGRATING SURVEILLANCE & RESPONSE TO SEASONAL INFLUENZA
$1,000,000Monir Islam · World Health Organization · U51 · FY2011 · IP
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia
$1,000,000Jodi K Craigo · Cytoagents, Inc. · R44 · FY2021 · AI